A biomarker-based diagnostic and treatment platform for differentiating and managing inflammatory bowel disease subtypes

This technology uses HD5 and MMP-7 biomarkers in tissue samples to accurately distinguish Crohn’s disease from ulcerative colitis, enabling precise diagnosis and guiding personalized treatment for inflammatory bowel disease patients.

Background

Inflammatory bowel disease (IBD) encompasses chronic, relapsing inflammatory disorders of the gastrointestinal tract, most notably ulcerative colitis (UC) and Crohn’s disease (CD). These two conditions differ in their pathological features, affected regions, and clinical management. Accurate differentiation between UC and CD is essential, as treatment strategies, surgical interventions, and long-term prognoses vary significantly. However, a considerable proportion of patients present with overlapping symptoms and inconclusive findings on endoscopy, imaging, and histopathology, leading to a diagnosis of indeterminate colitis (IC). This diagnostic ambiguity can delay appropriate therapy and complicate patient management, highlighting the need for more precise and reliable diagnostic tools in the field of gastroenterology.

Current diagnostic approaches for distinguishing UC from CD rely heavily on a combination of clinical assessment, endoscopic visualization, radiologic imaging, and histopathologic examination of tissue biopsies. Despite these resources, up to 30% of IBD cases remain indeterminate at initial presentation, and retrospective studies have shown that a significant number of patients are misclassified, sometimes resulting in inappropriate surgical interventions such as ileal pouch anal anastomosis (IPAA) in CD patients, which can lead to poor outcomes and complications. The lack of specific, objective biomarkers means that clinicians often face uncertainty, and the risk of misdiagnosis can result in suboptimal treatment, increased morbidity, and greater healthcare costs. Thus, there is a critical unmet need for molecular diagnostic methods that can accurately and reproducibly distinguish between UC and CD to guide optimal patient care.

Technology

This technology offers a comprehensive diagnostic and treatment platform for inflammatory bowel disease (IBD), specifically designed to distinguish between ulcerative colitis (UC) and Crohn’s disease (CD), including Crohn’s colitis (CC). It leverages the differential expression of two key biomarkers: Human α-Defensin-5 (HD5) and Matrix Metalloproteinase-7 (MMP-7). In practice, tissue or fluid samples from patients are analyzed using immunohistochemistry, ELISA, PCR, or related molecular techniques to quantify HD5 and MMP-7 levels. Elevated HD5 and/or low MMP-7 indicate CD, while low HD5 and/or elevated MMP-7 point to UC. This molecular signature enables clinicians to accurately classify ambiguous or indeterminate cases, guiding the selection of optimal treatment strategies. The platform is supported by diagnostic kits containing specific antibodies, reagents, and protocols for clinical implementation, ensuring reproducibility and ease of use in healthcare settings.

What differentiates this technology is its ability to resolve a longstanding clinical challenge: the accurate differentiation of UC and CD, which is critical for effective treatment planning and surgical decision-making. Traditional diagnostic methods often leave up to 30% of IBD cases indeterminate, leading to delayed or inappropriate therapy. By focusing on HD5 and MMP-7—biomarkers with distinct expression patterns in UC and CD—this solution delivers a high degree of diagnostic precision, validated by retrospective studies showing a 96% positive predictive value for reclassifying indeterminate cases. Furthermore, the integration of diagnostic results with tailored treatment recommendations ensures that patients receive therapies specifically suited to their disease subtype, reducing the risk of complications and improving long-term outcomes. This molecular approach represents a significant advancement over conventional histopathology and clinical assessment, offering a robust, personalized framework for managing IBD.

Benefits

  • Enables accurate differentiation between ulcerative colitis (UC) and Crohn’s disease (CD), including Crohn’s colitis (CC), using specific biomarkers HD5 and MMP-7.
  • Improves diagnostic precision for patients with indeterminate colitis, reducing misdiagnosis and inappropriate treatment.
  • Guides personalized treatment strategies tailored to the specific IBD subtype, enhancing therapeutic effectiveness.
  • Supports informed surgical decision-making, such as suitability for ileal pouch anal anastomosis (IPAA) surgery, minimizing postoperative complications.
  • Utilizes multiple validated measurement techniques (IHC, ELISA, PCR) for flexible and reliable biomarker quantification.
  • Provides kits and assays for clinical implementation, facilitating widespread adoption of the diagnostic method.
  • Offers a molecular diagnostic approach that overcomes limitations of conventional clinical, endoscopic, and histopathologic evaluations.

Applications

  • IBD subtype diagnostic testing
  • Personalized IBD treatment planning
  • Indeterminate colitis classification
  • Companion diagnostic kit development

Additional info

This diagnostic and treatment system differentiates inflammatory bowel disease subtypes. It quantifies Human α-Defensin-5 (elevated in Crohn’s disease) and Matrix Metalloproteinase-7 (elevated in ulcerative colitis) in patient tissue samples. These biomarker levels provide a molecular signature to accurately classify the disease, thereby guiding personalized therapeutic strategies and improving patient outcomes.